Group 1 - Precision medicine is reshaping the economic landscape in the Asia-Pacific region, with an estimated direct economic investment of approximately 1.45 trillion RMB (200 billion USD) in China's pharmaceutical value chain over the next decade [1] - The sector is expected to create up to 142,000 high-skilled jobs and generate an additional 870 billion RMB (120 billion USD) in indirect economic benefits [1][2] - Targeted antibody drugs, cell therapy, gene therapy, and companion diagnostics are identified as key areas for investment and growth [2][4] Group 2 - The investment in precision medicine will enhance healthcare accessibility and reduce medical expenses by approximately 216 billion RMB (30 billion USD), alleviating pressure on China's medical resources [1][3] - The development of precision medicine is a long-term process that will not only benefit patients but also upgrade medical infrastructure and create high-quality employment opportunities [3][5] - The Chinese government plays a crucial role in optimizing drug approval processes and enhancing the regulatory framework to support innovative therapies [6][8] Group 3 - The rise of AI technology is providing new opportunities for the intelligent transformation of the healthcare industry, which is essential for the development of precision medicine [7][8] - There is a need for improved data sharing and connectivity among medical institutions to facilitate the effective use of clinical and genetic data [7][8] - The global emphasis on data security and privacy protection necessitates compliance with regional policies and regulations, especially concerning cross-border data flow [8][9]
1.45万亿精准医学投资浪潮来袭:如何重塑医疗价值链?
Sou Hu Cai Jing·2025-07-25 03:34